Loading company financials…
NYSE · Pharmaceutical Preparations · CIK 0000001800
$108.33
-3.68% · delayed 15 min
$187.88B market value
What this company does
ABBOTT LABORATORIES develops and makes medicines. It took in $44.33B last year, which makes it a large company. Of every dollar it sells, about 15 cents is left as profit.
Financial health
Strong finances across the board.
From ABBOTT LABORATORIES's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +5.7%
$41.95B to $44.33B
Deteriorated: -51.3%
$13.40B to $6.52B
Improved: +1.0 pts
55.4% to
It makes a profit rather than burning through money.
$6.52B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$9.57B cash from operations
Its debt is small next to the cash the business produces.
about 0.5 years of cash flow to clear
A widely used bankruptcy-risk model places it well clear of distress.
Altman Z 5.01
It keeps less of each sale as profit than it did a year ago.
31.9% → 14.7%
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 9% a year for the next 10 years. Over the last 10 years it grew by about 15% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 15 cents of every dollar of sales as profit, earning $6.52B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It pays out 63 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 43% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $6.52B and generated $9.57B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Major event announcement(8-K) | 2026-08-20 | 2026-08-20 |
| Quarterly report(10-Q) | 2026-07-28 | 2026-06-30 |
Financial figures are from ABT's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
5.01
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.51
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −17.2 pts
31.9% to 14.7%
Improved: +16.4%
$6.35B to $7.39B
Improved: -21.6%
$12.63B to $9.90B
Improved: +11.9%
$7.62B to $8.52B
2 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 7% and 11%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.2% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Slowly. Sales grew 5.7% last year.
No. Its borrowings would take under a year of cash flow to clear. For every $1 it owes, it owns $2.51 in assets.
Around average. Investors pay $28.8 for every $1 of yearly profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-07-16 | 2026-07-16 |
| Quarterly report(10-Q) | 2026-04-29 | 2026-03-31 |
| Major event announcement(8-K) | 2026-04-27 | 2026-04-24 |
| Major event announcement(8-K) | 2026-04-17 | 2026-04-10 |
| Major event announcement(8-K) | 2026-04-16 | 2026-04-16 |
| Major event announcement(8-K) | 2026-03-23 | 2026-03-23 |
| Shareholder voting information(DEF 14A) | 2026-03-13 | 2026-04-24 |
| Major event announcement(8-K) | 2026-03-09 | 2026-03-09 |
| Major event announcement(8-K) | 2026-02-26 | 2026-02-23 |
| Major event announcement(8-K) | 2026-02-20 | 2026-02-20 |
| Annual report(10-K) | 2026-02-20 | 2025-12-31 |
| Major event announcement(8-K) | 2026-01-22 | 2026-01-22 |
| Major event announcement(8-K) | 2025-12-12 | 2025-12-12 |
| Major event announcement(8-K) | 2025-11-21 | 2025-11-18 |
| Major event announcement(8-K) | 2025-11-20 | 2025-11-19 |
| Quarterly report(10-Q) | 2025-10-29 | 2025-09-30 |
| Major event announcement(8-K) | 2025-10-15 | 2025-10-15 |
| Quarterly report(10-Q) | 2025-07-30 | 2025-06-30 |
Coverage from the last 30 days
Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery
Yahoo Finance ·
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Yahoo Finance ·
How Much Upside Can BSX Stock's Growth Deliver?
Yahoo Finance ·
Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
Yahoo Finance ·
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
Yahoo Finance ·
The Wide Divide Priced Into Boston Scientific Stock
Yahoo Finance ·
Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy
Yahoo Finance ·
3 Reasons to Sell PACB and 1 Stock to Buy Instead
Yahoo Finance ·
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Yahoo Finance ·
Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report?
Yahoo Finance ·
Medtronic Begins Fiscal 2027 With a Beat-and-Raise, Validating Growth Acceleration, RBC Says
Yahoo Finance ·
GEHC Wins CE Mark for Photonova Spectra, Expands International Reach
Yahoo Finance ·
Primary sources and further research